← Back to Patent Explorer
US4619942A Expired / Lapsed US ⏱️ 0.0 years remaining

Inhibition of Respiratory Syncytial virus-induced cell fusion by amidino compounds

Assignee: University of North Carolina at Chapel Hill
•
Filing: 1983-08-08
•
Granted: 1986-10-28
•
Expires: 2003-08-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A number of aromatic mono- and bis-amidines are capable of blocking cell fusion induced by Respiratory Syncytial (RS) virus. Suitable amidino compounds include those selected from the group consisting of 1-4-di(4-amidinophenoxy)-2-butanol; bis(5-amidino-2-benzimidazolyl)methane; 1,2-bis(5-amidino-2-benzimidazolyl)ethane; 5-amidino-indole; 5-amidinobenzimidazole, 5-amidino-1-methylindole and 5-amidino-1-(4-amidinobenzyl)indole. The most powerful of the compounds, bis(5-amidino-2-benzimidazolyl)methane (BABIM), is able to achieve complete suppression of syncytium formation at a concentration of 1 mu M. Inhibition occurs in RS virus-infected Hep-2 cells as well as CV-1 cells. BABIM also causes a significant retardation of RS virus penetration, but does not interfere with adsorption. Addition of the amidines after the penetration of RS virus does not affect single cycle yields. The compounds may be used in the prophylactic control of RS virus in man.

Inventors

  • 👤 Richard R. Tidwell
  • 👤 Edward J. Dubovi
  • 👤 Joachim D. Geratz

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 13:19
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/13; A61K31/155; A61K31/335; A61K31/34; A61K31/41; A61K31/415

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 40 words
A method for the treatment of respiratory syncytial virus-induced cell fusion which comprises administering to a host in need of said treatment an effective amount of an aromatic amidine compound selected from the group consisting of 1-4-di(4-amidinophenoxy)-2-butanol; 5-amidino-benzimidazole; and 5-amidino-1-(4-amidinobenzyl)indole.
Claim 2
Independent Claim 40 words
A method for the treatment of respiratory syncytial virus-induced cell fusion which comprises administering to a host in need of said treatment an effective amount of an aromatic amidine compound selected from the group consisting of 1-4-di(4-amidinophenoxy)-2-butanol; 5-amidino-benzimidazole; and 5-amidino-1-(4-amidinobenzyl)indole.
Claim 3
Dependent Claim 11 words
The method of claim 1 wherein the host is a human.
Claim 4
Dependent Claim 10 words
The method of claim 1, wherein said amidine is 5-amidino-1(4-amidinobenzyl)indole.
Claim 5
Dependent Claim 21 words
The method of claim 1 wherein said amidine is administered in an effective amount ranging from about 1.0 to 10.0 μM.
Claim 6
Dependent Claim 12 words
The method of claim 1 wherein the mode of administration is oral.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-10-27 1990-04-28 1990-10-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-10-27 1994-04-28 1994-10-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-10-27 1998-04-28 1998-10-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag